SUPN | Supernus PharmaceuticalsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history

$28.15
-$13.77 (-32.85%)

Supernus Pharmaceuticals (SUPN) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2018.

The 50 SMA has sat below the 200 on the daily since Jun 2026, with no cross projected inside the 30 bars Cruxta tracks. On both the daily and the 4-hour, price sits below the 50 and the 200; on the weekly it is between the two.

Timeframe summary

Daily as of 3 Nov 16:00 ET

Price
below both $28.15 vs 50 $42.15 / 200 $47.18
Projection
No cross projected
Test
No active test
Last cross
Death cross 9 Jun 2026 ยท projected 20 bars out

Weekly as of 30 Oct 16:00 ET

Price
between the two $41.92 vs 50 $47.30 / 200 $37.18
Projection
No cross projected
Test
No active test
Last cross
Golden cross week of 16 Dec 2024 ยท projected 20 bars out

4-hour as of 3 Nov 16:00 ET

Price
below both $28.15 vs 50 $41.11 / 200 $44.40
Projection
No cross projected
Test
No active test
Last cross
Death cross 29 Apr 2026 ยท projected 12 bars out

Cross history

33
crosses on record since 2018
16 golden17 death
Full cross history โ†’
CrossedDirectionTimeframeProjectedCross test
9 Jun 2026Death moderatedaily20 bars outNot tested
29 Apr 2026Death4-hour12 bars outNot tested
22 Dec 2025Golden4-hour19 bars outNot tested
15 Dec 2025Death4-hour25 bars outNot tested
18 Aug 2025Golden steepdaily26 bars outNot tested

About SUPN

ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$30.5M
4-hour coverageYes, since Oct 2025
History on recordSince 2018
SectorHealthcare
Cap bandmid

Cruxta · 50/200 moving-average crosses on US equities. Recorded crosses are observations. Projected crosses are projections, not advice.